Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Net Income (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Net Income for 13 consecutive years, with -$572471.0 as the latest value for Q3 2025.

  • On a quarterly basis, Net Income fell 111.44% to -$572471.0 in Q3 2025 year-over-year; TTM through Dec 2025 was -$759118.0, a 26.92% increase, with the full-year FY2025 number at -$1.3 million, down 90.72% from a year prior.
  • Net Income was -$572471.0 for Q3 2025 at Regen BioPharma, down from -$167292.0 in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$13047.0 in Q1 2021 to a low of -$572471.0 in Q3 2025.
  • A 5-year average of -$182475.8 and a median of -$128529.0 in 2022 define the central range for Net Income.
  • Peak YoY movement for Net Income: soared 93.72% in 2021, then crashed 812.52% in 2022.
  • Regen BioPharma's Net Income stood at -$141432.0 in 2021, then plummeted by 240.25% to -$481226.0 in 2022, then surged by 69.88% to -$144932.0 in 2023, then crashed by 255.6% to -$515384.0 in 2024, then fell by 11.08% to -$572471.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Net Income are -$572471.0 (Q3 2025), -$167292.0 (Q2 2025), and -$19355.0 (Q1 2025).